Table 3

Multivariable Cox regression clinical stage IV NSCLC (subtypes of systemic therapy); (aHR (95% CI)) for mortality associated with time-to-treatment

Time-to-treatment quartiles (days)Stage IV chemotherapy and/or immunotherapy (N=3715)Stage IV targeted therapy (N=1553)
aHR* (95% CI)P valueaHR† (95% CI)P value
1 (0–21 days)Ref-Ref-
2 (22–35 days)0.87 (0.79 to 0.97)0.00810.97 (0.81 to 1.16)0.711
3 (36–49 days)0.80 (0.72 to 0.89)<0.00010.95 (0.78 to 1.15)0.59
4 (>49 days)0.72 (0.64 to 0.81)<0.00010.96 (0.79 to 1.17)0.7004
  • *Time-to-treatment adjusted for gender, age, socioeconomic status, performance status, histology, distant metastasis (cM1a vs cM1b/cM1c).

  • †Time-to-treatment adjusted for gender, age, performance status, histology, distant metastasis (cM1a vs cM1b/cM1c).

  • aHR, adjusted HR; NSCLC, non-small cell lung cancer.